AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
2d
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
or KarXT. This news “may also prove to be a substantial positive” for Neurocrine (NBIX) “if – and it’s admittedly a huge IF – the company can successfully navigate” its own pending Phase 3 program, ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Bristol-Myers Squibb Company PFD CONV 2 (OTCPK:BMYMP) had declared $0.50/share quarterly dividend Payable Dec. 2; for shareholders of record Nov. 5; ex-div Nov. 5. See BMYMP Dividend Scorecard, Yield ...
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback